AstraZeneca Falls 16% as Drug Trial Falters

Shareholders have suffered a rollercoaster ride recently as AstraZeneca’s share price fell 15% this morning. Ketan Patel, fund manager at EdenTree, told Morningstar that this setback will put further pressure on CEO Pascal Soriot, who promised much when he rebuffed a takeover bid from Pfizer in 2014.